首页> 美国卫生研究院文献>Neuro-Oncology >EMBR-17. DE-INTENSIFICATION OF RADIOTHERAPY IN RIGOROUSLY DEFINED LOW-RISK WNT-SUBGROUP MEDULLOBLASTOMA IS ASSOCIATED WITH UNACCEPTABLY HIGH RISK OF NEURAXIAL FAILURE: RESULTS FROM THE PROSPECTIVE FOR-WNT STUDY
【2h】

EMBR-17. DE-INTENSIFICATION OF RADIOTHERAPY IN RIGOROUSLY DEFINED LOW-RISK WNT-SUBGROUP MEDULLOBLASTOMA IS ASSOCIATED WITH UNACCEPTABLY HIGH RISK OF NEURAXIAL FAILURE: RESULTS FROM THE PROSPECTIVE FOR-WNT STUDY

机译:搭配-17。在严格定义的低风险Wnt-subgromoup medulloblastoma的放射治疗的解除愈合与无可受欢迎的神经衰竭风险有关:来自WNT研究的前瞻性研究结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Medulloblastoma is a heterogenous disease comprising four molecular subgroups (WNT, SHH, Group 3, and Group 4) with varying outcomes. Excellent long-term survival (>90%) has prompted de-intensification of therapy in WNT-subgroup medulloblastoma globally. FOR-WNT is one such prospective study (CTRI/2017/12/010767) testing the hypothesis that focal conformal radiotherapy (RT) (54Gy/30 fractions/6-weeks) with avoidance of upfront craniospinal irradiation (CSI) followed by standard adjuvant chemotherapy significantly reduces RT-related late toxicity without unduly compromising survival in low-risk WNT-subgroup medulloblastoma (residual tumor <1.5cm2 with no evidence of metastases in children aged between 3–16 years).
机译:Medulloblastoma是包含四种分子亚组(Wnt,Shh,第3组和第4组)的异源性疾病,其结果不同。优异的长期生存(> 90%)促进在全球WNT-亚组髓质母细胞瘤的治疗进行解除。对于WNT是一种这样的前瞻性研究(CTRI / 2017/12 / 010767)测试局灶性保形放疗(RT)(54GY / 30分数/ 6周),避免前期颅辐射(CSI),然后是标准佐剂的假设化学疗法显着降低了RT相关的晚期毒性,不会过度损害低风险的WNT-亚组Medulloblastoma(残留肿瘤<1.5cm2,没有3-16岁的儿童转移的证据)。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号